NEW YORK, Feb. 17, 2023 /PRNewswire/ -- The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.
Read the full report: https://www.reportlinker.com/p06051389/?utm_source=PRN
Global Kidney Cancer Drugs Market to Reach $8.1 Billion by 2030
In the changed post COVID-19 business landscape, the global market for Kidney Cancer Drugs estimated at US$5.6 Billion in the year 2022, is projected to reach a revised size of US$8.1 Billion by 2030, growing at aCAGR of 4.8% over the period 2022-2030. Targeted Therapy, one of the segments analyzed in the report, is projected to record 5.1% CAGR and reach US$5.6 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Immunotherapy segment is readjusted to a revised 4.2% CAGR for the next 8-year period.
The U.S. Market is Estimated at $1.5 Billion, While China is Forecast to Grow at 8.2% CAGR
The Kidney Cancer Drugs market in the U.S. is estimated at US$1.5 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 8.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.5% and 4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.
Select Competitors (Total 12 Featured)
- Bayer AG
- Bristol-Myers Squibb Company
- Eisai Co., Ltd.
- Exelixis, Inc.
- Novartis International AG
- Pfizer, Inc.
Read the full report: https://www.reportlinker.com/p06051389/?utm_source=PRN
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Kidney Cancer Drugs - Global Key Competitors Percentage Market
Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Kidney Cancer Drugs by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 2: World Historic Review for Kidney Cancer Drugs by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 3: World 18-Year Perspective for Kidney Cancer Drugs by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2012, 2023 & 2030
Table 4: World Recent Past, Current & Future Analysis for
Targeted Therapy by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 5: World Historic Review for Targeted Therapy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 6: World 18-Year Perspective for Targeted Therapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2023 & 2030
Table 7: World Recent Past, Current & Future Analysis for
Immunotherapy by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 8: World Historic Review for Immunotherapy by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2021 and
% CAGR
Table 9: World 18-Year Perspective for Immunotherapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2023 & 2030
Table 10: World Recent Past, Current & Future Analysis for
Angiogenesis Inhibitors by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR
Table 11: World Historic Review for Angiogenesis Inhibitors by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 12: World 18-Year Perspective for Angiogenesis Inhibitors
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2023 & 2030
Table 13: World Recent Past, Current & Future Analysis for mTOR
Inhibitors by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 14: World Historic Review for mTOR Inhibitors by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 15: World 18-Year Perspective for mTOR Inhibitors by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2023 & 2030
Table 16: World Recent Past, Current & Future Analysis for
Monoclonal Antibodies by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR
Table 17: World Historic Review for Monoclonal Antibodies by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 18: World 18-Year Perspective for Monoclonal Antibodies
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2023 & 2030
Table 19: World Recent Past, Current & Future Analysis for
Cytokine Immunotherapy (IL-2) by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 20: World Historic Review for Cytokine Immunotherapy
(IL-2) by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2021 and % CAGR
Table 21: World 18-Year Perspective for Cytokine Immunotherapy
(IL-2) by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2023 &
2030
Table 22: World Kidney Cancer Drugs Market Analysis of Annual
Sales in US$ Million for Years 2012 through 2030
III. MARKET ANALYSIS
UNITED STATES
Kidney Cancer Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United States for 2023 (E)
Table 23: USA Recent Past, Current & Future Analysis for Kidney
Cancer Drugs by Therapeutic Class - Targeted Therapy and
Immunotherapy - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 24: USA Historic Review for Kidney Cancer Drugs by
Therapeutic Class - Targeted Therapy and Immunotherapy Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 25: USA 18-Year Perspective for Kidney Cancer Drugs by
Therapeutic Class - Percentage Breakdown of Value Sales for
Targeted Therapy and Immunotherapy for the Years 2012, 2023 &
2030
Table 26: USA Recent Past, Current & Future Analysis for Kidney
Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors,
mTOR Inhibitors, Monoclonal Antibodies and Cytokine
Immunotherapy (IL-2) - Independent Analysis of Annual Sales in
US$ Million for the Years 2022 through 2030 and % CAGR
Table 27: USA Historic Review for Kidney Cancer Drugs by
Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors,
Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 28: USA 18-Year Perspective for Kidney Cancer Drugs by
Pharmacologic Class - Percentage Breakdown of Value Sales for
Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies
and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 &
2030
CANADA
Table 29: Canada Recent Past, Current & Future Analysis for
Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and
Immunotherapy - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 30: Canada Historic Review for Kidney Cancer Drugs by
Therapeutic Class - Targeted Therapy and Immunotherapy Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 31: Canada 18-Year Perspective for Kidney Cancer Drugs by
Therapeutic Class - Percentage Breakdown of Value Sales for
Targeted Therapy and Immunotherapy for the Years 2012, 2023 &
2030
Table 32: Canada Recent Past, Current & Future Analysis for
Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis
Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine
Immunotherapy (IL-2) - Independent Analysis of Annual Sales in
US$ Million for the Years 2022 through 2030 and % CAGR
Table 33: Canada Historic Review for Kidney Cancer Drugs by
Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors,
Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 34: Canada 18-Year Perspective for Kidney Cancer Drugs by
Pharmacologic Class - Percentage Breakdown of Value Sales for
Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies
and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 &
2030
JAPAN
Kidney Cancer Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Japan for 2023 (E)
Table 35: Japan Recent Past, Current & Future Analysis for
Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and
Immunotherapy - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 36: Japan Historic Review for Kidney Cancer Drugs by
Therapeutic Class - Targeted Therapy and Immunotherapy Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 37: Japan 18-Year Perspective for Kidney Cancer Drugs by
Therapeutic Class - Percentage Breakdown of Value Sales for
Targeted Therapy and Immunotherapy for the Years 2012, 2023 &
2030
Table 38: Japan Recent Past, Current & Future Analysis for
Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis
Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine
Immunotherapy (IL-2) - Independent Analysis of Annual Sales in
US$ Million for the Years 2022 through 2030 and % CAGR
Table 39: Japan Historic Review for Kidney Cancer Drugs by
Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors,
Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 40: Japan 18-Year Perspective for Kidney Cancer Drugs by
Pharmacologic Class - Percentage Breakdown of Value Sales for
Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies
and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 &
2030
CHINA
Kidney Cancer Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in China for 2023 (E)
Table 41: China Recent Past, Current & Future Analysis for
Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and
Immunotherapy - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 42: China Historic Review for Kidney Cancer Drugs by
Therapeutic Class - Targeted Therapy and Immunotherapy Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 43: China 18-Year Perspective for Kidney Cancer Drugs by
Therapeutic Class - Percentage Breakdown of Value Sales for
Targeted Therapy and Immunotherapy for the Years 2012, 2023 &
2030
Table 44: China Recent Past, Current & Future Analysis for
Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis
Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine
Immunotherapy (IL-2) - Independent Analysis of Annual Sales in
US$ Million for the Years 2022 through 2030 and % CAGR
Table 45: China Historic Review for Kidney Cancer Drugs by
Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors,
Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 46: China 18-Year Perspective for Kidney Cancer Drugs by
Pharmacologic Class - Percentage Breakdown of Value Sales for
Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies
and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 &
2030
EUROPE
Kidney Cancer Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Europe for 2023 (E)
Table 47: Europe Recent Past, Current & Future Analysis for
Kidney Cancer Drugs by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR
Table 48: Europe Historic Review for Kidney Cancer Drugs by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2021 and % CAGR
Table 49: Europe 18-Year Perspective for Kidney Cancer Drugs by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2012, 2023 & 2030
Table 50: Europe Recent Past, Current & Future Analysis for
Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and
Immunotherapy - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 51: Europe Historic Review for Kidney Cancer Drugs by
Therapeutic Class - Targeted Therapy and Immunotherapy Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 52: Europe 18-Year Perspective for Kidney Cancer Drugs by
Therapeutic Class - Percentage Breakdown of Value Sales for
Targeted Therapy and Immunotherapy for the Years 2012, 2023 &
2030
Table 53: Europe Recent Past, Current & Future Analysis for
Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis
Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine
Immunotherapy (IL-2) - Independent Analysis of Annual Sales in
US$ Million for the Years 2022 through 2030 and % CAGR
Table 54: Europe Historic Review for Kidney Cancer Drugs by
Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors,
Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 55: Europe 18-Year Perspective for Kidney Cancer Drugs by
Pharmacologic Class - Percentage Breakdown of Value Sales for
Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies
and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 &
2030
FRANCE
Kidney Cancer Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in France for 2023 (E)
Table 56: France Recent Past, Current & Future Analysis for
Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and
Immunotherapy - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 57: France Historic Review for Kidney Cancer Drugs by
Therapeutic Class - Targeted Therapy and Immunotherapy Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 58: France 18-Year Perspective for Kidney Cancer Drugs by
Therapeutic Class - Percentage Breakdown of Value Sales for
Targeted Therapy and Immunotherapy for the Years 2012, 2023 &
2030
Table 59: France Recent Past, Current & Future Analysis for
Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis
Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine
Immunotherapy (IL-2) - Independent Analysis of Annual Sales in
US$ Million for the Years 2022 through 2030 and % CAGR
Table 60: France Historic Review for Kidney Cancer Drugs by
Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors,
Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 61: France 18-Year Perspective for Kidney Cancer Drugs by
Pharmacologic Class - Percentage Breakdown of Value Sales for
Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies
and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 &
2030
GERMANY
Kidney Cancer Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Germany for 2023 (E)
Table 62: Germany Recent Past, Current & Future Analysis for
Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and
Immunotherapy - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 63: Germany Historic Review for Kidney Cancer Drugs by
Therapeutic Class - Targeted Therapy and Immunotherapy Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 64: Germany 18-Year Perspective for Kidney Cancer Drugs
by Therapeutic Class - Percentage Breakdown of Value Sales for
Targeted Therapy and Immunotherapy for the Years 2012, 2023 &
2030
Table 65: Germany Recent Past, Current & Future Analysis for
Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis
Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine
Immunotherapy (IL-2) - Independent Analysis of Annual Sales in
US$ Million for the Years 2022 through 2030 and % CAGR
Table 66: Germany Historic Review for Kidney Cancer Drugs by
Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors,
Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 67: Germany 18-Year Perspective for Kidney Cancer Drugs
by Pharmacologic Class - Percentage Breakdown of Value Sales
for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal
Antibodies and Cytokine Immunotherapy (IL-2) for the Years
2012, 2023 & 2030
ITALY
Table 68: Italy Recent Past, Current & Future Analysis for
Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and
Immunotherapy - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 69: Italy Historic Review for Kidney Cancer Drugs by
Therapeutic Class - Targeted Therapy and Immunotherapy Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 70: Italy 18-Year Perspective for Kidney Cancer Drugs by
Therapeutic Class - Percentage Breakdown of Value Sales for
Targeted Therapy and Immunotherapy for the Years 2012, 2023 &
2030
Table 71: Italy Recent Past, Current & Future Analysis for
Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis
Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine
Immunotherapy (IL-2) - Independent Analysis of Annual Sales in
US$ Million for the Years 2022 through 2030 and % CAGR
Table 72: Italy Historic Review for Kidney Cancer Drugs by
Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors,
Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 73: Italy 18-Year Perspective for Kidney Cancer Drugs by
Pharmacologic Class - Percentage Breakdown of Value Sales for
Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies
and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 &
2030
UNITED KINGDOM
Kidney Cancer Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United Kingdom for 2023 (E)
Table 74: UK Recent Past, Current & Future Analysis for Kidney
Cancer Drugs by Therapeutic Class - Targeted Therapy and
Immunotherapy - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 75: UK Historic Review for Kidney Cancer Drugs by
Therapeutic Class - Targeted Therapy and Immunotherapy Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 76: UK 18-Year Perspective for Kidney Cancer Drugs by
Therapeutic Class - Percentage Breakdown of Value Sales for
Targeted Therapy and Immunotherapy for the Years 2012, 2023 &
2030
Table 77: UK Recent Past, Current & Future Analysis for Kidney
Cancer Drugs by Pharmacologic Class - Angiogenesis Inhibitors,
mTOR Inhibitors, Monoclonal Antibodies and Cytokine
Immunotherapy (IL-2) - Independent Analysis of Annual Sales in
US$ Million for the Years 2022 through 2030 and % CAGR
Table 78: UK Historic Review for Kidney Cancer Drugs by
Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors,
Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 79: UK 18-Year Perspective for Kidney Cancer Drugs by
Pharmacologic Class - Percentage Breakdown of Value Sales for
Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies
and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 &
2030
SPAIN
Table 80: Spain Recent Past, Current & Future Analysis for
Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and
Immunotherapy - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 81: Spain Historic Review for Kidney Cancer Drugs by
Therapeutic Class - Targeted Therapy and Immunotherapy Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 82: Spain 18-Year Perspective for Kidney Cancer Drugs by
Therapeutic Class - Percentage Breakdown of Value Sales for
Targeted Therapy and Immunotherapy for the Years 2012, 2023 &
2030
Table 83: Spain Recent Past, Current & Future Analysis for
Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis
Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine
Immunotherapy (IL-2) - Independent Analysis of Annual Sales in
US$ Million for the Years 2022 through 2030 and % CAGR
Table 84: Spain Historic Review for Kidney Cancer Drugs by
Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors,
Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 85: Spain 18-Year Perspective for Kidney Cancer Drugs by
Pharmacologic Class - Percentage Breakdown of Value Sales for
Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies
and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 &
2030
RUSSIA
Table 86: Russia Recent Past, Current & Future Analysis for
Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and
Immunotherapy - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 87: Russia Historic Review for Kidney Cancer Drugs by
Therapeutic Class - Targeted Therapy and Immunotherapy Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 88: Russia 18-Year Perspective for Kidney Cancer Drugs by
Therapeutic Class - Percentage Breakdown of Value Sales for
Targeted Therapy and Immunotherapy for the Years 2012, 2023 &
2030
Table 89: Russia Recent Past, Current & Future Analysis for
Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis
Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine
Immunotherapy (IL-2) - Independent Analysis of Annual Sales in
US$ Million for the Years 2022 through 2030 and % CAGR
Table 90: Russia Historic Review for Kidney Cancer Drugs by
Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors,
Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 91: Russia 18-Year Perspective for Kidney Cancer Drugs by
Pharmacologic Class - Percentage Breakdown of Value Sales for
Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies
and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 &
2030
REST OF EUROPE
Table 92: Rest of Europe Recent Past, Current & Future Analysis
for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy
and Immunotherapy - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 93: Rest of Europe Historic Review for Kidney Cancer
Drugs by Therapeutic Class - Targeted Therapy and Immunotherapy
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2021 and % CAGR
Table 94: Rest of Europe 18-Year Perspective for Kidney Cancer
Drugs by Therapeutic Class - Percentage Breakdown of Value
Sales for Targeted Therapy and Immunotherapy for the Years
2012, 2023 & 2030
Table 95: Rest of Europe Recent Past, Current & Future Analysis
for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis
Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine
Immunotherapy (IL-2) - Independent Analysis of Annual Sales in
US$ Million for the Years 2022 through 2030 and % CAGR
Table 96: Rest of Europe Historic Review for Kidney Cancer
Drugs by Pharmacologic Class - Angiogenesis Inhibitors, mTOR
Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy
(IL-2) Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2021 and % CAGR
Table 97: Rest of Europe 18-Year Perspective for Kidney Cancer
Drugs by Pharmacologic Class - Percentage Breakdown of Value
Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal
Antibodies and Cytokine Immunotherapy (IL-2) for the Years
2012, 2023 & 2030
ASIA-PACIFIC
Kidney Cancer Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Asia-Pacific for 2023 (E)
Table 98: Asia-Pacific Recent Past, Current & Future Analysis
for Kidney Cancer Drugs by Geographic Region - Australia,
India, South Korea and Rest of Asia-Pacific Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR
Table 99: Asia-Pacific Historic Review for Kidney Cancer Drugs
by Geographic Region - Australia, India, South Korea and Rest
of Asia-Pacific Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2021 and % CAGR
Table 100: Asia-Pacific 18-Year Perspective for Kidney Cancer
Drugs by Geographic Region - Percentage Breakdown of Value
Sales for Australia, India, South Korea and Rest of
Asia-Pacific Markets for Years 2012, 2023 & 2030
Table 101: Asia-Pacific Recent Past, Current & Future Analysis
for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy
and Immunotherapy - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 102: Asia-Pacific Historic Review for Kidney Cancer Drugs
by Therapeutic Class - Targeted Therapy and Immunotherapy
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2021 and % CAGR
Table 103: Asia-Pacific 18-Year Perspective for Kidney Cancer
Drugs by Therapeutic Class - Percentage Breakdown of Value
Sales for Targeted Therapy and Immunotherapy for the Years
2012, 2023 & 2030
Table 104: Asia-Pacific Recent Past, Current & Future Analysis
for Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis
Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine
Immunotherapy (IL-2) - Independent Analysis of Annual Sales in
US$ Million for the Years 2022 through 2030 and % CAGR
Table 105: Asia-Pacific Historic Review for Kidney Cancer Drugs
by Pharmacologic Class - Angiogenesis Inhibitors, mTOR
Inhibitors, Monoclonal Antibodies and Cytokine Immunotherapy
(IL-2) Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2021 and % CAGR
Table 106: Asia-Pacific 18-Year Perspective for Kidney Cancer
Drugs by Pharmacologic Class - Percentage Breakdown of Value
Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal
Antibodies and Cytokine Immunotherapy (IL-2) for the Years
2012, 2023 & 2030
AUSTRALIA
Kidney Cancer Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Australia for 2023 (E)
Table 107: Australia Recent Past, Current & Future Analysis for
Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and
Immunotherapy - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 108: Australia Historic Review for Kidney Cancer Drugs by
Therapeutic Class - Targeted Therapy and Immunotherapy Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 109: Australia 18-Year Perspective for Kidney Cancer
Drugs by Therapeutic Class - Percentage Breakdown of Value
Sales for Targeted Therapy and Immunotherapy for the Years
2012, 2023 & 2030
Table 110: Australia Recent Past, Current & Future Analysis for
Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis
Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine
Immunotherapy (IL-2) - Independent Analysis of Annual Sales in
US$ Million for the Years 2022 through 2030 and % CAGR
Table 111: Australia Historic Review for Kidney Cancer Drugs by
Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors,
Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 112: Australia 18-Year Perspective for Kidney Cancer
Drugs by Pharmacologic Class - Percentage Breakdown of Value
Sales for Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal
Antibodies and Cytokine Immunotherapy (IL-2) for the Years
2012, 2023 & 2030
INDIA
Kidney Cancer Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in India for 2023 (E)
Table 113: India Recent Past, Current & Future Analysis for
Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy and
Immunotherapy - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 114: India Historic Review for Kidney Cancer Drugs by
Therapeutic Class - Targeted Therapy and Immunotherapy Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 115: India 18-Year Perspective for Kidney Cancer Drugs by
Therapeutic Class - Percentage Breakdown of Value Sales for
Targeted Therapy and Immunotherapy for the Years 2012, 2023 &
2030
Table 116: India Recent Past, Current & Future Analysis for
Kidney Cancer Drugs by Pharmacologic Class - Angiogenesis
Inhibitors, mTOR Inhibitors, Monoclonal Antibodies and Cytokine
Immunotherapy (IL-2) - Independent Analysis of Annual Sales in
US$ Million for the Years 2022 through 2030 and % CAGR
Table 117: India Historic Review for Kidney Cancer Drugs by
Pharmacologic Class - Angiogenesis Inhibitors, mTOR Inhibitors,
Monoclonal Antibodies and Cytokine Immunotherapy (IL-2) Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2021 and % CAGR
Table 118: India 18-Year Perspective for Kidney Cancer Drugs by
Pharmacologic Class - Percentage Breakdown of Value Sales for
Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies
and Cytokine Immunotherapy (IL-2) for the Years 2012, 2023 &
2030
SOUTH KOREA
Table 119: South Korea Recent Past, Current & Future Analysis
for Kidney Cancer Drugs by Therapeutic Class - Targeted Therapy
and Immunotherapy - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 120: South Korea Historic Review for Kidney Cancer Drugs
by Therapeutic Class - Targeted Therapy and Immunotherapy
Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06051389/?utm_source=PRN
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
![](https://rt.prnewswire.com/rt.gif?NewsItemId=NY17272&Transmission_Id=202302171110PR_NEWS_USPR_____NY17272&DateId=20230217)
Share this article